- Home
- NTIP vs TPST Comparison
NTIP vs TPST Comparison
Compare NTIP & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTIP
- TPST
- Stock Information
- Founded
- NTIP 1990
- TPST 2011
- Country
- NTIP United States
- TPST United States
- Employees
- NTIP N/A
- TPST N/A
- Industry
- NTIP Multi-Sector Companies
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- NTIP Miscellaneous
- TPST Health Care
- Exchange
- NTIP Nasdaq
- TPST Nasdaq
- Market Cap
- NTIP 28.6M
- TPST 33.0M
- IPO Year
- NTIP 1998
- TPST N/A
- Fundamental
- Price
- NTIP $1.25
- TPST $7.13
- Analyst Decision
- NTIP
- TPST Hold
- Analyst Count
- NTIP 0
- TPST 3
- Target Price
- NTIP N/A
- TPST $30.00
- AVG Volume (30 Days)
- NTIP 13.9K
- TPST 251.1K
- Earning Date
- NTIP 08-11-2025
- TPST 08-07-2025
- Dividend Yield
- NTIP 8.00%
- TPST N/A
- EPS Growth
- NTIP N/A
- TPST N/A
- EPS
- NTIP N/A
- TPST N/A
- Revenue
- NTIP $250,000.00
- TPST N/A
- Revenue This Year
- NTIP N/A
- TPST N/A
- Revenue Next Year
- NTIP N/A
- TPST N/A
- P/E Ratio
- NTIP N/A
- TPST N/A
- Revenue Growth
- NTIP N/A
- TPST N/A
- 52 Week Low
- NTIP $1.16
- TPST $5.35
- 52 Week High
- NTIP $1.78
- TPST $30.03
- Technical
- Relative Strength Index (RSI)
- NTIP 51.66
- TPST 51.19
- Support Level
- NTIP $1.21
- TPST $6.73
- Resistance Level
- NTIP $1.30
- TPST $7.18
- Average True Range (ATR)
- NTIP 0.05
- TPST 0.31
- MACD
- NTIP -0.00
- TPST -0.00
- Stochastic Oscillator
- NTIP 64.29
- TPST 84.48
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.